Literature DB >> 9309404

Gastroesophageal reflux disease in patients with columnar-lined esophagus.

R B Ter1, D O Castell.   

Abstract

Columnar-lined esophagus or Barrett's esophagus is closely associated with gastroesophageal reflux disease. Animal and human studies have shown not only acid but duodenogastroesophageal reflux acting in synergy with acid causes the most esophageal injury. Patients with Barrett's esophagus manifest typical and atypical symptoms of reflux. Ten percent to 25%, however, have clinically silent reflux. Early diagnosis is essential for this disease as it is a risk factor for the development of adenocarcinoma of the esophagus.

Entities:  

Mesh:

Year:  1997        PMID: 9309404     DOI: 10.1016/s0889-8553(05)70313-7

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  5 in total

1.  No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  The real value of lower esophageal sphincter measurement for predicting acid gastroesophageal reflux or Barrett's esophagus.

Authors:  Oscar Alonso; Diego Hernández; Enrique Moreno; Alejandro Manrique; Almudena Moreno; Alvaro García-Sesma; Jorge Calvo
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

3.  Evidence based case reports. Undergraduates in Cork have to submit them during their course.

Authors:  I J Perry
Journal:  BMJ       Date:  1998-11-14

4.  Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins.

Authors:  Zongli Zheng; Helena Nordenstedt; Nancy L Pedersen; Jesper Lagergren; Weimin Ye
Journal:  Gastroenterology       Date:  2006-11-17       Impact factor: 22.682

5.  Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux.

Authors:  M Nilsson; R Johnsen; W Ye; K Hveem; J Lagergren
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.